Non-hodgkin's lymphoma in children: Correlation of CNS disease with initial presentation

Authors

  • John J. Hutter Jr.,

    Associate Director of Oncology, Corresponding author
    1. Oncology Center, The Children's Hospital, Denver, CO. and Junior Faculty Clinical Fellow, American Cancer Society
    2. Oncology Center, The Children's Hospital, Denver CO
    • Associate Director of Oncology, Oncology Center, The Children's Hospital, 1056 East Nineteenth Avenue, Denver, CO 80218
    Search for more papers by this author
  • Blaise E. Favara,

    Pathologist and Director of Laboratories
    1. The Children's Hospital Denver, CO
    2. Oncology Center, The Children's Hospital, Denver CO
    Search for more papers by this author
  • Michael Nelson,

    1. Resident in Pediatrics, Fitzsimons Army Medical Center, Denver, CO
    2. Oncology Center, The Children's Hospital, Denver CO
    Search for more papers by this author
  • Charlene P. Holton

    Director of Oncology
    1. The Children's Hospital, and Clinical Assistant Professor of Pediatrics, University of Colorado Medical Center, Denver, CO
    2. Oncology Center, The Children's Hospital, Denver CO
    Search for more papers by this author

Abstract

The clinical and histopathological findings in 26 children with non-Hodgkin's lymphoma without initial marrow involvement are reviewed. A marked male predominance similar to that observed in previous series was noted. Biopsy material was classified according to the recommendations of Rappaport in 22 cases. All have diffuse lymphomas, and 16 of 22 patients had diffuse, poorly-differentiated, lymphocytic lymphoma. Twelve of 26 patients had involvement of the mediastinum as part of their initial presentation. Of these 12, 5 developed lymphomatous involvement of the central nervous system prior to the development of leukemic transformation of the bone marrow. This observation suggests that prophylactic therapy against CNS relapse be considered for children with mediastinal non-Hodgkin's lymphoma, even in the absence of initial marrow involvement.

Ancillary